Ibrutinib, Lenalidomide, and Rituximab in Relapsed Mantle Cell Lymphoma

This study on long-term follow-up in relapsed mantle cell lymphoma involved a combination of lenalidomide, rituximab, and ibrutinib. Conducted in the Nordic countries, it showed a median progression-free survival of 70.4 months, even in TP53 mutated cases. Elin Forsgren, Uppsala University, presents the study in this MEDtalk at EHA 2024.